Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 4;12:100. doi: 10.1038/s41467-020-20317-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — tat-GluA2_3Y peptide or a Scrambled control (2.25 μmol/kg in saline, IV) was delivered 30 min prior to recording on the exposure day. A Stratum oriens stimulation evoked fEPSPs in GluA2_3Y (red) or Scrambled (blue) treated rats. Solid marker indicates the cross-channel average, while each channel is plotted every 5 stimulations and offset for clarity. B Cumulative distribution of oriens-evoked fEPSPs showed no difference between treatment groups during or after novelty exposure (red, GluA2_3Y n = 26 channels; blue, Scrambled, n = 31 channels). C Per-animal proportion of channels exceeding 1 standard deviation of the channel’s baseline variance at each stimulation. Shaded area represents the proportion of channels expected to be above or below 1 standard deviation based on a normal distribution. (n = 4 GluA2_3Y, n = 5 Scrambled). D Proportion of channels exceeding 1 standard deviation above (top graph) or below (bottom graph) baseline in each epoch. No significant change in distribution was observed in either treatment group during or after novelty exposure treatment (n = 4 GluA2_3Y, n = 5 Scrambled). E Stratum radiatum evoked fEPSPs in GluA2_3Y (red) and Scrambled (blue) treated rats. F Cumulative distribution of radiatum-evoked fEPSPs showed a widespread decrease during novelty exposure (solid) and on return to the familiar chamber (dashed) that was blocked by GluA2_3Y treatment (red, n = 34 channels; blue, Scrambled, n = 29 channels). G Per-animal proportion of channels exceeding 1 standard deviation of the channel’s baseline variance at each stimulation (n = 5 GluA2_3Y, n = 4 Scrambled). H Proportion of channels averaged in each epoch indicate a specific increase in the proportion of channels lower than 1 standard deviation from baseline in the radiatum channel during after exposure to the novel environment that was blocked by GluA2_3Y treatment (n = 5 GluA2_3Y, n = 4 Scrambled). *p < 0.05, **p < 0.01 follow-up t-test (two-tail) comparison between group for epochs after significant group by epoch ANOVA interaction, and ks-test for distribution. Error bars represent ± SEM.